Haya therapeutics sa
WebHAYA Therapeutics SA Route De La Corniche 6 SuperLab Suisse – Batiment Serine 1066 Epalinges, Lausanne Vaud, Switzerland [email protected] San Diego HAYA … WebHAYA Therapeutics SA: HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.
Haya therapeutics sa
Did you know?
WebMay 20, 2024 · HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the … WebFounded Date 2024. Founders Daniel Blessing, Samir Ounzain. Operating Status Active. Last Funding Type Seed. Legal Name HAYA Therapeutics SA. Company Type For …
WebOct 2, 2024 · 16.12.2024 The 18 most promising biotech startups, according to investors (TOP 100) 14.10.2024 International and seasoned board members for Switzerland … WebHAYA Therapeutics raised $5,000,000 / Seed from 4See Ventures and 6 other investors . ... HAYA Therapeutics SA raised $18,000,000 / Seed from 4See Ventures and 5 other investors . Discover more funding rounds . View All . Details. Edit Details Section. Founded Date 2024; Operating Status Active; Investor Type Venture Capital Lists Featuring ...
WebSep 15, 2024 · HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today … WebFeb 16, 2024 · LAUSANNE, Switzerland & SAN DIEGO, (BUSINESS WIRE) -- HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today ...
WebNov 2, 2024 · 2 HAYA Therapeutics SA, Lausanne, Vaud 1066, Switzerland. PMID: 31932317 PMCID: PMC7605224 (available on 2024-11-01) DOI: 10.1101/cshperspect.a037374 Abstract The exquisite transcriptional control of developmental gene programs is critical for hardwiring the complex expression patterns …
WebSep 15, 2024 · LAUSANNE, Switzerland and SAN DIEGO, September 15, 2024--Long non-coding RNA company HAYA Therapeutics, SA says Metagenomi CEO Brian C. Thomas, Ph.D., has joined as Chairperson of the Board of ... irons newsWebFeb 16, 2024 · LAUSANNE, Switzerland & SAN DIEGO, February 16, 2024 -- ( BUSINESS WIRE )-- HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs ... irons mill farmstead new wilmington paWebSep 15, 2024 · HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Brian C. Thomas, Ph.D., has joined HAYA as ... port width mismatchWebOct 2, 2024 · 16.12.2024 The 18 most promising biotech startups, according to investors (TOP 100) 14.10.2024 International and seasoned board members for Switzerland (startupticker.ch) 10.02.2024 New US Laboratory and funding for HAYA Therapeutics (startupticker.ch) 09.02.2024 HAYA closes USD 5M seed extension led by Humboldt … port whmWebFind company research, competitor information, contact details & financial data for Haya Therapeutics SA of Epalinges, VAUD. Get the latest business insights from Dun & … port whitby rentalsWebHAYA Therapeutics SA has 6 investors including Apollo Health Ventures and Viva BioInnovator. How much funding has HAYA Therapeutics SA raised to date? HAYA … port whiteWebHAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer. The company’s discovery engine focuses on long non-coding RNAs (lncRNAs) within the “dark matter”of the ... port wholesale